
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
PHARMASEAL, a new provider of clinical trial management and governance solutions, has launched Engility CTMS, the first product to be released from its Engility B2B platform. This new CTMS has been designed in hopes to increase the level of governance and control that organizations demand from their management systems to enable effective oversight of their clinical trials.
Read the full release






